uniQure (QURE) Announces Completion of Strategic Review; Will Refocus Resources, Restructure R&D Organization

uniQure (QURE) PT Cut to $12 at Chardan Capital Markets; 'Buy' Maintained on Simplification

Chardan Capital Markets analyst Gbola Amusa lowered its price target on uniQure BV (NASDAQ: QURE) to $12.00 (from $20.00) on drug discontinuations after a strategic review but maintained a Buy on the simplifying of the company.

Amusa commented, "uniQure is simplifying its company structure, and will de-emphasize Sanfilippo B and Parkinson's disease... More